This novel inhibitor demonstrates that inhibition of GCN2 sensitizes cancer cells with low basal-level expression of asparagine synthetase to other agents such as the antileukemic agent L-asparaginase in acute lymphocytic leukemia. This evidence concerns the gene ASPG and cancer.